Parabilis (PBLS) director granted 20,215 stock options at $20 strike

Rhea-AI Filing Summary

Parabilis Medicines director Yeshwant Krishna received a grant of stock options as compensation. The award covers 20,215 options to buy common stock at an exercise price of $20.00 per share, expiring on June 8, 2036. These options vest and become exercisable in full on the earlier of June 9, 2027 or the company’s next annual meeting of stockholders, contingent on his continued service. After this grant, he holds 20,215 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Yeshwant Krishna

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,215	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 20,215 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 20,215 options Exercise price: $20.00 per share Expiration date: June 8, 2036 +2 more

5 metrics

Options granted 20,215 options Stock Option (Right to Buy) grant on June 9, 2026

Exercise price $20.00 per share Exercise price for common stock under the option

Expiration date June 8, 2036 Option expiration for the granted stock options

Post-grant derivative holdings 20,215 derivative securities Total stock options held directly after this grant

Vesting trigger date June 9, 2027 or next annual meeting Earlier date determines full vesting, subject to continued service

Key Terms

Stock Option (Right to Buy), exercise price, Common Stock, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"Security title is listed as "Stock Option (Right to Buy)" in the filing."

exercise price financial

"The transaction shows an exercise price of 20.0000 per underlying share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Common Stock financial

"The underlying security title is identified as Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

annual meeting of stockholders financial

"Options vest on June 9, 2027 or the date of the issuer's next annual meeting of stockholders."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yeshwant Krishna

(Last) (First) (Middle)

C/O PARABILIS MEDICINES, INC.

30 ACORN PARK DRIVE, 6TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02140

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Parabilis Medicines, Inc. [ PBLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$20	06/09/2026		A		20,215		(1)	06/08/2036	Common Stock	20,215	$0	20,215	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

	/s/ Teresa Jurgensen, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Parabilis Medicines (PBLS) report for Yeshwant Krishna?

Parabilis Medicines reported that director Yeshwant Krishna received a grant of 20,215 stock options. These options give him the right to buy common shares at $20.00 each as part of his compensation package, rather than reflecting an open-market stock purchase.

How many Parabilis Medicines (PBLS) options were granted to the director and at what price?

The director was granted 20,215 stock options with an exercise price of $20.00 per share. This means he can later purchase up to 20,215 common shares at $20.00, regardless of the market price at the time of exercise, if the options vest.

When do Yeshwant Krishna’s Parabilis (PBLS) stock options vest and become exercisable?

The options vest and become exercisable in full on the earlier of June 9, 2027 or the date of Parabilis Medicines’ next annual meeting of stockholders. Vesting is conditioned on his continued service as of that vesting date, according to the filing footnote.

What is the expiration date of the Parabilis (PBLS) stock options granted to the director?

The granted stock options expire on June 8, 2036 if not exercised. After that date, they can no longer be used to purchase Parabilis common stock at the $20.00 exercise price, effectively ending their value to the holder.

Is the Parabilis (PBLS) Form 4 transaction an open-market buy or a compensation grant?

The reported transaction is a compensation-related grant, not an open-market buy. The Form 4 lists transaction code A, described as a grant, award, or other acquisition, with a zero-dollar grant price and a $20.00 per share exercise price for future purchases.